Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
NCT07146646 · Case Comprehensive Cancer Center · PHASE2 · suspended · last registry update 2026-10-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Interim Analysis” | – | Registry record, Case Comprehensive Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TYMP within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Results posted on the registry: Academic and Community Cancer Research United, Paclitaxel + Ramucirumab (NCT04660760)
- 2026-11-03Phase 3 first posted: Genfleet Therapeutics (Shanghai) Inc., GFH375 + Cetuximab + Fruquintinib (NCT07913360)
- 2026-11-02Also stopped (suspended): M.D. Anderson Cancer Center, Nivolumab + Bevacizumab (NCT07011550)
- 2026-10-05Also stopped (withdrawn): Biotech Pharmaceutical Co., Ltd., Nimotuzumab injection + Placebo (NCT06343116)
- 2026-09-18Also stopped (suspended): Holy Stone Healthcare Co., Ltd, CA102N + TAS-102 (NCT06039202)
- 2026-08-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2026-08-26Also stopped (terminated): Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2026-08-14Also stopped (terminated): Astellas Pharma Global Development, Inc., ASP1570 + pembrolizumab (NCT05083481)
- 2026-07-28Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-M07D1 + Regorafenib (NCT07730489)
- 2026-07-23Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., IBI363 + bevacizumab + Investigator's choice of therapy (NCT07722494)
- 2026-07-22Results posted on the registry: Amgen, Sotorasib + Panitumumab (NCT05198934)
- 2026-06-10Results posted on the registry: Australasian Gastro-Intestinal Trials Group, Regorafenib + Nivolumab (NCT04879368)
- 2026-04-24Phase 3 first posted: EMD Serono Research & Development Institute, Inc., Precemtabart tocentecan + Bevacizumab (NCT07549412)
- 2026-04-13Phase 3 first posted: AbbVie, Telisotuzumab adizutecan + Bevacizumab (NCT07525206)
- 2026-03-19Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., TQB2102 Injection + Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets (NCT07483684)
- 2026-02-10Results posted on the registry: Roswell Park Cancer Institute, Irinotecan + Bevacizumab (NCT04109924)
- 2026-02-03Also stopped (suspended): Gruppo Oncologico del Nord-Ovest, 5-Fluorouracil continuous infusion FOLFOXIRI schedule + 5-Fluorouracil bolus FOLFOX schedule (NCT05062889)
- 2026-01-22Phase 3 first posted: Jiangsu Simcere Pharmaceutical Co., Ltd., Suvemcitug injection, trifluridine/tipiracil tablets + Suvemcitug placebo injection, trifluridine/tipiracil tablets (NCT07361003)
- 2026-01-21Results posted on the registry: National Cancer Center Hospital East, trifluridine and tipiracil + Placebo (NCT04457297)
- 2025-12-10Results posted on the registry: Providence Health & Services, TAS 102 + Oxaliplatin (NCT04417699)
- 2025-12-08Phase 3 first posted: Federation Francophone de Cancerologie Digestive, trifluridine/tipiracil + fruquintinib (NCT07270991)
- 2025-11-04Also stopped (terminated): Baylor Research Institute, All patients- TAS-102 (NCT04042714)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision